[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alcohol-related-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alcohol-related-disorders":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,49,74,119,158,201,222,246,270,302,331,351,382,415,445],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100392576","covid-19-pandemic-impact-on-alcohol-pia---a-natural-history-study-100392576",false,"NCT04391816","COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Participants who have enrolled in the NIAAA Natural History Protocol (14-AA-0181) and completed screening and phenotyping assessments.\n2. Willing and able to complete frequent (weekly to monthly) surveys either online or by phone.\n\nEXCLUSION CRITERIA:\n\nAs this is a natural history protocol, there are no formal exclusionary criteria for this study. Participants who are determined by the interviewer to be uncooperative or unable to provide consent via telephone will not be enrolled into the study.",true,"ALL","18 Years","100 Years",{"count":20,"type":21},1500,"ESTIMATED","OBSERVATIONAL","Background:\n\nThe SARS-CoV-2 virus has caused a pandemic infection called COVID-19. It is a global threat to people, communities, and health systems. Researchers are concerned about the mental health effects of the pandemic. They want to learn more about how it is affecting people s alcohol use and problems, and how it may continue to affect them over time.\n\nObjective:\n\nTo study the impact of the COVID-19 pandemic on alcohol use and consequences in individuals across the spectrum of alcohol use and those with alcohol use disorder.\n\nEligibility:\n\nParticipants who have been screened under the NIAAA Screening, Assessment and Management Protocol (14-AA-0181)\n\nDesign:\n\nParticipants will complete a baseline survey by phone. It will ask about alcohol use, alcohol dependence, and stress. It covers 2 time periods: the 12 months before the pandemic started and the time since it started.\n\nParticipants will get an ID code and a link to an online survey. They will complete the online survey within a week of the phone survey.\n\nParticipants will complete a series of online surveys over 24 months. For the first year, surveys will be completed weekly for the first 4 weeks, then biweekly for the next 8 weeks, and then every 1-2 months for the rest of the year. For the second year, surveys will be completed every 6 months. Surveys will cover the following topics:\n\n* Alcohol use and its consequences\n* Other substance use\n* Stress\n* Impact of the COVID-19 pandemic\n* Pain\n* Physical health\n* Sleep\n* Quality of life.\n\nBecause the course of the pandemic may change, the frequency of the surveys may change.\n\nParticipation lasts 2 years.",[25,26,27,28],"Alcohol Drinking","Alcohol-Related Disorders","Pandemic","Psychological Stress",[30,31,32,33,34,35],"Coronavirus","Alcohol Use Disorder","SARS-CoV2","Stress","Social Isolation","Natural History","RECRUITING","2026-06-23",{"date":39,"type":40},"2026-06-24","ACTUAL",{"date":42,"type":40},"2020-06-03",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","NIH",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":73,"locationsCount":48},"100217454","characterization-imaging-instruments-in-alcoholics-and-non-alcoholics-100217454","NCT02108080","Characterization Imaging Instruments in Alcoholics and Non-Alcoholics","Characterization Imaging Instruments for Addiction Neuroimaging Assessments","* INCLUSION CRITERIA:\n\nAll adult participants must be:\n\n* Age 18 years or older,\n* Have been pre-screened, determined eligible for any NIAAA study, or enrolled in any\n\nNIAAA study (including 14-AA-0181).\n\nEXCLUSION CRITERIA:\n\nAs this is a natural history protocol, there are no exclusionary criteria for this study.\n\nParticipants should have been tested negative prior to the time of consent and study procedures using an alcohol breathalyzer, urine drug (UDT) and, when applicable, pregnancy tests. Individuals with a positive breath alcohol concentration (BrAC), UDT, or pregnancy test will be re-scheduled or withdrawn from the study.\n\nUpon completion of the consent, the participant will be invited for the study session. On the study session day, the following exclusion criteria will be applied.\n\n-Exclusion criteria for MR scan\\*\n\n* Positive BrAC#,\n* Positive urine drug test (UDT) # for benzodiazepines, cocaine, methamphetamines, and opiates for outpatients. Positive UDT for benzodiazepines is not exclusionary for the inpatients. It is common that the inpatients who are treated for AUD withdrawal are treated with benzodiazepines. Positive THC would also not be exclusionary for this study since it tends to be detected over the long period of time after use. However, we will make note of these for the data analysis purposes.\n* Task performance (behavioral, fMRI) only: cleared based on neuromotor examination,\n* Presence of ferromagnetic objects in the body that are contraindicated for MRI of the head (pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments),\n* Cannot lie comfortably flat on back for up to 2 hours in the MRI scanner,\n* Uncomfortable in enclosed spaces (has claustrophobia) such that they would feel discomfort in the scanner,\n* Women: are pregnant#,\n* Are left-handed.\n* Inpatient participants with alcohol use disorder who have symptoms of alcohol withdrawal as indicated by the most recent measurement within the past 30 days, measured by the Clinical Institute Withdrawal Assessment (CIWA-Ar) score \\> 8.\n\n  * Subjects excluded from MR scan may still perform the behavioral tasks which would otherwise be performed in the scanner, if they qualify for behavioral tasks. To avoid undue discomfort, burden, and inconvenience this information, if available, can be gathered from routine clinical care or other NIAAA clinical studies and data.\n\n    * Participants who meet this exclusion criterion will not participate in any part of this study at the time. They will be re-scheduled for a future date(s) when they do not meet any of the exclusionary criterion.",{"count":57,"type":21},1000,"Background:\n\n\\- People with alcoholism have differences in their brains compared with healthy people. People who are dependent on alcohol also perform differently on behavioral tasks. Researchers want to find out more about these differences. They also want to see if these differences are related to DNA.\n\nObjective:\n\n\\- To see if differences in brain structure relate to personality and behavior differences in people with and without alcohol dependence.\n\nEligibility:\n\n\\- Adults age 18 and older.\n\nDesign:\n\n* Participants will visit the NIH Clinical Center once during the study.\n* Participants will be screened with a medical history, EKG, and physical exam. They will give blood and urine samples and undergo a psychiatric interview.\n* Participants will be asked about their alcohol drinking, to see if they have an alcohol use disorder.\n* Participants will play three computerized games. Some will play these games inside a magnetic resonance imaging (MRI) scanner.\n* MRI: strong magnetic field and radio waves take pictures of the brain. Participants lie on a table that slides in and out of a cylinder. They will be in the scanner for about 90 minutes. They may lie still for up to 20 minutes at a time. The scanner makes loud knocking noises. They will get earplugs.",[60,25,26,61,62],"Alcohol Dependence","Alcoholism","Brain Mapping",[64,65,66,67,68,35],"Alcohol","Biomarkers","Adults","Phenotype","Imaging",{"date":39,"type":40},{"date":71,"type":40},"2014-07-10",{"date":44,"type":21},{"name":46,"class":47},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":15,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100641150","launchpad-supporting-healthy-decisions-and-preventing-drug-use-after-high-school-100641150","NCT07655609","LaunchPad: Supporting Healthy Decisions and Preventing Drug Use After High School","Preventing Drug Use Onset and Progression Toward Addiction During a Critical Transition Period: Optimizing an Online Intervention for High School Seniors","Schools:\n\n* Public or private school in the U.S. enrolling 12th grade students\n* Agree to (1) provide us contact information for students and parents (or to send study information to students and parents themselves), (2) identify a school contact person (typically a school counselor) who will work with us to carry out the study (recruitment, pretest survey, intervention deployment, posttest survey), and (3) either provide school time to complete the intervention or integrate the intervention into a class (e.g., as an out-of-class assignment)\n\nStudents:\n\n* Enrolled as a 12th grade student at one of the participating schools\n* Have not completed a previous version of the intervention before\n* Between the ages of 15 and 21 years of age","15 Years","21 Years",{"count":84,"type":21},5000,"INTERVENTIONAL",[87],"NA","LaunchPad is an online substance use prevention program for high school seniors. The program is designed to help seniors develop skills and make informed decisions as they transition from high school to young adulthood.\n\nThe purpose of this clinical trial is to learn whether individual LaunchPad lessons improve the specific attitudes, intentions, and skills they are designed to address. For example, researchers will examine whether the stress management lesson increases students' intentions to use healthy ways of managing stress.\n\nThe main question this study aims to answer is: Does each individual LaunchPad lesson improve the specific outcomes it was designed to address?\n\nResearchers will compare students who receive a particular lesson with students who do not receive that lesson to determine whether the lesson changes the intended outcome.\n\nParticipants will:\n\n* Complete a brief baseline survey\n* Complete two introductory online lessons\n* Complete one or more randomly assigned LaunchPad lessons\n* Complete a brief follow-up survey\n\nAll surveys and lessons will be completed online.",[90,26,91,92],"Substance-related Disorders","Tobacco Use Disorder","Marijuana Use",[94,95,64,96,97,98,99,100,101,102,103,104,105,106,107],"Adolescence","Adolescent and Young Adult","Behavior","Decision Making","Development","Expectancy","High School Student","Intervention","Marijuana","Schools","Substance Use Prevention","Transition out of high school","Multi-phase Optimization Strategy","Normative Education","NOT_YET_RECRUITING","2026-06-22",{"date":111,"type":40},"2026-06-25",{"date":113,"type":21},"2026-09-01",{"date":115,"type":21},"2029-04-30",{"name":117,"class":118},"Prevention Strategies, LLC","INDUSTRY",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":15,"sex":126,"minAge":17,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":85,"phases":130,"briefSummary":131,"conditions":132,"keywords":139,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":48},"100635054","carrii-native-intervention-optimization-trial-100635054","NCT07547696","CARRII Native Intervention Optimization Trial","CARRII Native Intervention Optimization Trial 3-month Factorial Experiment With 512 Participants Randomized to 8 Conditions","Inclusion Criteria:\n\n* Native American\u002FAmerican Indian\u002FAlaska Native,\n* who are not surgically sterile,\n* who report alcohol consumption at risk levels and risk for pregnancy in the past 90 days due to having sex with a man with inconsistent, ineffective, or no contraception.\n* Participants must have access to the Internet via a mobile device they can access daily\n\nExclusion Criteria:\n\n* cognitive disorders including mental retardation, dementia, or psychotic disorders that could impair ability to understand the intervention material or give informed consent.","FEMALE","44 Years",{"count":129,"type":21},512,[87],"The purpose of this study is to identify the best combination of new intervention components to use with CARRII, the first automated online intervention for alcohol-exposed pregnancies (AEP). This intervention is specifically designed for Native women and others who can become pregnant. Our goal is to maximize the effectiveness of the online intervention while keeping costs manageable for Native communities.",[133,134,26,135,136,137,138],"Fetal Alcohol Spectrum Disorders","Pregnancy","Drinking, Alcohol","Contraception Behavior","Alcohol Exposed Pregnancy","Sexual Behavior",[140,141,142,143,144,145,146,147,148],"Native American","female","adult","contraception","alcohol","digital intervention","mobile health (mHealth)","optimization","risk reduction","2026-06-18",{"date":37,"type":40},{"date":152,"type":40},"2026-06-02",{"date":154,"type":21},"2028-07-30",{"name":156,"class":157},"University of Virginia","OTHER",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":85,"phases":167,"briefSummary":168,"conditions":169,"keywords":178,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100509219","improving-alcohol-and-substance-use-care-access-outcome-equity-during-the-reproductive-years-100509219","NCT05910580","Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years","Improving Alcohol and Substance Use Care Access, Outcomes, and Equity During the Reproductive Years: A Type 1 Hybrid Trial in Family Planning Clinics","Inclusion Criteria:\n\n* Over the age of 18 years\n* U.S. residing\n* Have internet access (own a computer or smart phone)\n* Screen positive to one or more risky alcohol and substance use behaviors as determined by our standardized abbreviated instruments\n\nExclusion Criteria:\n\n* Not capable of communicating (reading, speaking, writing) in English or Spanish",{"count":166,"type":21},400,[87],"The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic.\n\nThe main questions it aims to answer are:\n\n* Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing?\n* Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity?\n* Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)?\n\nParticipants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months.\n\nResearchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.",[26,170,171,172,173,174,175,176,134,177],"Substance-Related Disorders","Mental Health","Reproductive Health","Sexual Health","Sexually Transmitted Diseases","Contraception","Maternal Health","Women's Health",[179,180,181,182,183,184,185,186,187,188,189,190],"Implementation Science","Mass Screening","Motivational Interviewing","Referral and Consultation","Quality of Health Care","Early Medical Intervention","Family Planning Services","Primary Health Care","Reproductive Health Services","Telemedicine","Preconception Care","Young Adult","2026-06-12",{"date":193,"type":40},"2026-06-15",{"date":195,"type":40},"2025-07-03",{"date":197,"type":21},"2027-05-31",{"name":199,"class":157},"Emory University",4,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":85,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":48},"100597023","external-facilitation-to-increase-prescribing-of-aud-medications-in-the-psychiatric-setting-100597023","NCT07053098","External Facilitation to Increase Prescribing of AUD Medications in the Psychiatric Setting","Inclusion Criteria:\n\n* For prescribers: working as a prescriber, non-prescribing clinician, or administrator at one of the three participating clinics.\n* For patients: has major mental illness (major depressive disorders, bipolar disorder, schizophrenia spectrum disorders, other psychotic disorders; posttraumatic stress disorder)\n* For patients: has Alcohol Use Disorder and is being treated in one of the three participating clinics.\n\nExclusion Criteria:\n\n* For all: age is less than 18 years old\n* For all: not able to complete informed consent","90 Years",{"count":209,"type":21},40,[87],"This project will pilot test an implementation facilitation intervention to increase prescribing of medications for alcohol use disorder (MAUD) in patients with major mental illness and alcohol use disorder in three psychiatry treatment clinics.",[26,213],"Psychiatric Disorder","2026-05-29",{"date":216,"type":40},"2026-06-03",{"date":218,"type":40},"2025-03-18",{"date":197,"type":21},{"name":221,"class":157},"University of Maryland, Baltimore",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":85,"phases":231,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":48},"100521519","phase-1-the-potential-therapeutic-effects-of-psychedelic-n-n-dimethyltryptamine-dmt-on-alcohol-use-disorder-aud-100521519","NCT06070649","The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)","Inclusion Criteria:\n\n* Diagnostic and Statistical Manual of Mental Disorders-5th edition (DSM-5) diagnosis of Alcohol Use Disorder\n* Medically healthy\n* Ability to provide consent\n\nExclusion Criteria:\n\n* Unstable medical conditions","65 Years",{"count":230,"type":21},63,[232],"PHASE1","This proposed study is a double-blind, randomized, placebo-controlled, parallel-group, laboratory study to determine the effects of DMT, plus psychotherapy, on Alcohol Use Disorder.",[235,26,236],"Alcohol Use Disorder (AUD)","Alcohol Use","2026-04-26",{"date":239,"type":40},"2026-04-28",{"date":241,"type":40},"2025-08-04",{"date":243,"type":21},"2026-08-01",{"name":245,"class":157},"Yale University",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":228,"enrollmentInfo":253,"targetDuration":4,"studyType":85,"phases":255,"briefSummary":256,"conditions":257,"keywords":258,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":48},"100564980","phase-1-diclofenac-dose-response-study-100564980","NCT06636227","Diclofenac Dose Response Study","Optimal Dosing, Tolerability, and Initial Efficacy of Diclofenac as a KMO Inhibitor in Individuals With Alcohol Use Disorder","Inclusion Criteria:\n\n* Age 21-65\n* Meet DSM-5 diagnostic criteria for current AUD of any severity (Mild, Moderate, or Severe)\n* In the 30-day period before enrollment, consume \\> 14 and \\> 7 standard drinks per week for men and women, respectively\n* In the 30-day period before enrollment, engage in heavy drinking (5 or more drinks for men, 4 or more drinks for women) ≥ 5 times per month\n\nExclusion Criteria:\n\n* Currently in treatment, a history of treatment within the 30 days before enrollment, or currently seeking immediate treatment for AUD\n* Current (last 12 months) DSM-5 diagnosis of SUD for any psychoactive substances other than alcohol, nicotine, and cannabis (cannabis use disorder, mild severity allowed; moderate and severe excluded)\n* Currently prescribed a psychotropic medication for the treatment of schizophrenia spectrum and other psychotic disorders, bipolar and related disorders\n* Lifetime DSM-5 diagnosis of schizophrenia spectrum and other psychotic disorders and bipolar and related disorders\n* Positive urine toxicology screen for the following substances: cocaine, opiates, amphetamines, methamphetamine, phencyclidine, barbiturates, benzodiazepine, methadone, and tricyclic antidepressants\n* Self-reported current daily use of opioids (including prescribed)\n* If female: pregnant, nursing, or with reproductive potential who refuses to use reliable methods of birth control throughout the study\n* Serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised\n* Any autoimmune disorder, inflammatory disorder, hypercoagulable state, cardiovascular disease or other medical condition (e.g., any cardiac, renal, or liver disease, uncontrolled hypertension, or diabetes) that may interfere with safe study participation and\u002For study aims. Specific examples of exclusionary medical conditions include but are not limited to:\n\n  1. Any lifetime history of 1) serious GI conditions, including ulcer disease, gastrointestinal bleeding, and clinically significant gastritis, or, 2) serious cardiovascular conditions, including heart failure, myocardial infarction, stroke, pulmonary embolism, blood clots, deep vein thrombosis, or clotting disorder, 3) liver disease or impaired liver function, and 4) renal disease or insufficiency\n  2. Current uncontrolled hypertension\n  3. AST and ALT \\> four times the upper limit of the normal range, or albumin, GFR, BUN, or creatinine 15% \\> the upper limit of the normal range\n  4. Clinically significant ECG findings, including clinically significant arrhythmia, atrioventricular block, prolonged QTc interval, or enlarged or hypertrophic heart\n  5. Serious brain conditions, including epilepsy, dementia and neurodegenerative diseases, traumatic brain injury (TBI), etc. TBI exclusionary criteria include: suffered a mild or moderate TBI within the last 12 months, a severe TBI at any point in their life, or a moderate TBI before the age of 12\n* Attempted suicide in the past 3 years and\u002For serious suicidal intention or plan within the past year\n* Currently on prescription medication that contraindicates use of diclofenac, including but not necessarily limited to: oral corticosteroids, anticoagulants, lithium, warfarin, aspirin (daily use), methotrexate, cyclosporine, ACE-inhibitors, diuretics like furosemide and thiazides, and any medication that significantly influences CYP2C9 enzyme activity (e.g., rifampin, voriconazole).\n* Previously known hypersensitivity, including gastroenteritis, asthma, and allergic-type reactions, to any NSAID and\u002For aspirin\n* Current daily use of any NSAID or regular pattern of near daily use within the past three months, regular use of a prebiotic or probiotic supplement and\u002For any antibiotic, prebiotic, or probiotic use within the last month\n* Any other circumstances that, in the opinion of the investigators, compromises participant safety, ability of the investigators to conduct the study as designed, and\u002For study integrity\n* Current or recent (within 3 months) participation in a clinical trial involving medication administration\n* Has below a 6th grade reading level\n* Within the last 3 months, tested positive for COVID-19 (i.e. the SARS-CoV-2 virus) and experienced common related symptoms",{"count":254,"type":21},24,[232],"The development of efficacious medications for AUD remains a high research priority with current emphases on identifying novel molecular targets and efficiently screening new compounds. Pharmacological modulation of the kynurenine pathway (KP) represents a promising novel target for AUD. The KP is a complex enzymatic cascade with each step producing biologically active metabolites that are critically involved in diverse physiological and pathological processes. Chronic alcohol exposure produces dysregulation of the KP, particularly as evidenced by decreased levels of the neuroprotective metabolite kynurenic acid (KYNA) and increased levels of the neurotoxic metabolite quinolinic acid (QUIN). This metabolic shift is associated with various alcohol-related pathologies in animals and humans. Thus, a medication that targets the KP to restore KYNA and attenuate QUIN levels may be an effective treatment for AUD. The enzyme kynurenine 3- monooxygenase (KMO) is a major gatekeeper of the KP and resultant KYNA levels. KMO inhibition shifts the KP towards KYNA production in brain and away from QUIN production. Critically, KMO inhibition in rodents, through its increase in brain KYNA levels, decreases alcohol self-administration, preference, cue-reactivity, and relapse behaviors. However, KMO-inhibitors have not been tested in humans because of presumed lack of availability. Diclofenac is an FDA-approved Non-Steroidal Anti-Inflammatory Drug that was recently discovered to inhibit KMO activity. Consistent with KMO inhibition, diclofenac increases KYNA levels in the brain and periphery of rodents. However, it remains unknown whether diclofenac increases KYNA levels and affects alcohol-related behaviors in humans at approved, safe dosages.\n\nInvestigators propose to conduct a human laboratory pilot study to test whether diclofenac can increase KYNA in individuals with AUD, and if so, which of 3 doses (50, 75, or 100 mg) most effectively increases KYNA. Individuals with AUD (n = 24) will complete four sessions where they receive diclofenac (50, 75, or 100 mg) or placebo. Investigators will examine increases in KYA levels and will also assess QUIN levels, alcohol craving, and negative mood.",[235,26],[259,26,61,260,170,261],"Alcohol use disorder (AUD)","Drinking Behavior","Chemically-Induced Disorders","2026-02-05",{"date":264,"type":40},"2026-02-09",{"date":266,"type":40},"2024-12-01",{"date":268,"type":21},"2026-08-31",{"name":221,"class":157},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":85,"phases":280,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":48},"100595955","phase-3-intervention-to-increase-intention-to-change-alcoholtobacco-use-in-veterans-with-chronic-disease-100595955","NCT07039175","Intervention to Increase Intention to Change Alcohol\u002FTobacco Use in Veterans With Chronic Disease","A Low-Cost, High-Access Intervention to Increase Intention to Change Alcohol\u002FTobacco Use Among Reticent Veterans Who Are Non-Responders to Brief Advice at High Risk Due to Chronic Conditions","MINDSET","Inclusion Criteria:\n\n* an active diagnosis of diabetes, cardiovascular disease (CVD), or a cardiovascular risk factor (hypertension {HTN}, hyperlipidemia {HLD}) AND signs of reticence to change their smoking and\u002For alcohol use as evidenced by the two consecutive prior screens being positive for hazardous (e.g., Alcohol Use Disorders Test-Consumption \\[AUDC\\], and\u002For smoking (I.e., whether they are a current smoker or not).\n* Confirmation of smoking and\u002For drinking status during telephone screening (e.g., Alcohol Use Disorders Test-Consumption \\[AUDC\\], and\u002For smoking (I.e., whether they are a current smoker or not).\n* Veteran\n* Age 18 years\n* utilize VA for medical care more than 1 time per year\n* are due to complete their smoking\u002Falcohol use screen in approximately 3 months (to ensure they will likely receive UC during intervention period)\n* a scheduled PC appointment within the intervention period.\n\nExclusion Criteria:\n\n* dementia or severe cognitive impairment per Problem List\n* significant visual impairment per Problem List\n* Other Exclusion criteria assessed by study staff during screening\u002Fself-report are:\n\n  * inability to communicate or read in English;\n  * Hearing impairment; and\n  * cognitive impairment or screening for cognitive impairment (\\>=weighted score of 10 on Blessed screener).",{"count":279,"type":21},270,[281],"PHASE3","Many Veterans who have chronic conditions like cardiovascular disease or diabetes smoke or drink too much alcohol, which can worsen the condition. Veterans are asked yearly about drinking\u002Fsmoking and providers provide a brief advice discussion focused on behavior change. However, many Veterans continue to drink or smoke, and are often not interested in higher-intensity, change-based referrals. The investigators recently piloted MINDSET, an intervention that fills this gap. MINDSET is a proactive, population-based intervention that uses a mailed packet with tailored education about how drinking\u002Fsmoking relate to the Veteran's condition (heart conditions and\u002For diabetes), followed by a brief motivational call. The investigators will test MINDSET's effectiveness versus usual primary care on outcomes including intention to change and substance use and evaluate the relationships between these and other variables over time.",[284,26],"Tobacco Smoking",[286,287,135,288,289,290,291],"Chronic Disease","Smoking","Cardiovascular Risk","Health Behavior","Medicine, Behavioral","telehealth","2025-12-23",{"date":294,"type":40},"2025-12-31",{"date":296,"type":40},"2025-10-01",{"date":298,"type":21},"2029-06-30",{"name":300,"class":301},"VA Office of Research and Development","FED",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":228,"enrollmentInfo":309,"targetDuration":4,"studyType":85,"phases":311,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":48},"100586544","comparing-combined-behavioral-intervention-and-ericksonian-hypnotherapy-for-alcohol-addiction-100586544","NCT06916754","Comparing Combined Behavioral Intervention and Ericksonian Hypnotherapy for Alcohol Addiction","Comparing the Efficacy of Combined Behavioral Intervention and Ericksonian Hypnotherapy in the Treatment of Alcohol Addiction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged between 18 and 65 years\n* Meets DSM-5 diagnostic criteria for Alcohol Use Disorder (mild to severe)\n* Medically and psychiatrically stable as determined by a clinician\n* Willing and able to participate in weekly sessions over a 12-week period\n* Provides informed consent\n\nExclusion Criteria:\n\n* Current diagnosis of a severe psychiatric disorder (e.g., psychotic disorder, bipolar I disorder)\n* Significant cognitive impairment that would interfere with treatment participation\n* Participation in another structured addiction treatment during the study period\n* Current use of psychotropic medications that may influence outcome measures (as assessed by the clinical team)\n* Unstable medical condition requiring immediate intervention\n* Pregnancy or planning to become pregnant during the study period",{"count":310,"type":21},90,[87],"This clinical study is being conducted to compare the effectiveness of two psychological treatments for alcohol addiction: Combined Behavioral Intervention (CBI) and Ericksonian Hypnotherapy (EH). The purpose of the study is to determine whether Ericksonian Hypnotherapy, a more personalized and indirect therapeutic method, is equal to or more effective than the gold-standard approach, Combined Behavioral Intervention, in helping individuals reduce their alcohol consumption and improve psychological well-being.\n\nAlcohol addiction is a serious condition that affects mental, emotional, and physical health. Many treatment options exist, but not all individuals respond in the same way. This study aims to evaluate two different types of therapy in a structured way, to better understand which works best, for whom, and under what circumstances.\n\nThe study will include 90 adult participants diagnosed with Alcohol Use Disorder (AUD). Participants will be randomly assigned to one of three groups: (1) a group receiving weekly sessions of Combined Behavioral Intervention, (2) a group receiving weekly sessions of Ericksonian Hypnotherapy, or (3) a control group receiving general educational materials about alcohol addiction. Treatment will last for 12 weeks, and all participants will be followed up three months after the last session to assess long-term effects.\n\nThroughout the study, researchers will measure changes in alcohol consumption, alcohol craving, mental health symptoms (such as depression and anxiety), quality of life, and motivation to change. The findings of this study may help improve the way alcohol addiction is treated by offering evidence on alternative approaches such as hypnotherapy.",[26,61,90],[315,316,317,181,318,319,320,321],"Ericksonian Hypnosis","Hypnotherapy","Cognitive Behavioral Therapy","Relapse Prevention","Craving","Substance Craving","Psychotherapy","2025-04-13",{"date":324,"type":40},"2025-04-16",{"date":326,"type":40},"2025-03-01",{"date":328,"type":21},"2026-02-01",{"name":330,"class":157},"Beykoz University",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":85,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":349,"locationsCount":48},"100487163","phase-1-phase-i-dose-escalation-study-of-dihydromyricetin-dhm-to-treat-alcohol-associated-liver-disease-100487163","NCT05623501","Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease","Inclusion Criteria:\n\n* No prior medical history of alcohol use disorder or alcohol-associated liver disease\n* Between 18-60 years old\n\nExclusion Criteria:\n\n* Weight below 50kg.\n* Advanced liver disease\n* Other acute liver diseases\n* HIV co-infection\n* History of pancreatic or biliary disease\n* Acute illness that would interfere with drug absorption\n* Pregnancy\n* Participants who are currently taking drugs with CYP3A4 effects\n* FIB-4 Index \\> 1.30\n* History of Alcohol Use Disorder (AUD) determined by score \\> 8 on AUDIT questionnaire","60 Years",{"count":339,"type":21},12,[232],"The current proposal is designed as a first-in-human Phase 1 open-label, dose-escalation study to assess the safety, pharmacokinetics, and the maximum tolerated dose of DHM among healthy volunteers using a purified form of DHM from a local cGMP compliant source (Master Herbs, Inc).",[26],"2024-08-28",{"date":345,"type":40},"2024-09-03",{"date":347,"type":21},"2024-09-15",{"date":294,"type":21},{"name":350,"class":157},"University of Southern California",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":358,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":85,"phases":362,"briefSummary":363,"conditions":364,"keywords":369,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":48},"100553484","centralized-virtual-sbirt-for-pediatric-primary-care-100553484","NCT06486688","Centralized Virtual SBIRT for Pediatric Primary Care","Virtual SBIRT for Pediatric Primary Care: Increasing Access to Screening, Brief Intervention and Referral to Treatment for Alcohol and Other Drug Use Via Telehealth","Inclusion Criteria:\n\n• The sample will include all adolescents aged 12 through 17 years seen for a Well Visit, who are at risk of AOD use disorder defined as endorsing monthly or more frequent AOD use OR any AOD use and past-two-week depressive symptoms or suicidality.\n\nExclusion Criteria:\n\n• N\u002FA - all adolescents with a Well Visit are eligible","12 Years","17 Years",{"count":361,"type":21},22320,[87],"Adolescent alcohol and other drug (AOD) use is a significant public health problem which contributes to high levels of mortality, morbidity and healthcare costs in young people, and identification and early intervention for these problems is critical to improving outcomes. Screening, Brief Intervention and Referral to Treatment (SBIRT) in pediatric primary care is an evidence-based strategy for addressing these problems, but has not been widely and systematically implemented, for a variety of reasons, including lack of training and staffing resources to support its implementation. This pragmatic, Type 1 Hybrid Comparative Effectiveness Implementation study will examine whether a centralized, virtually-delivered modality of SBIRT, rapidly accessible by multiple pediatric primary care clinics, can be cost-effectively implemented to improve early identification and treatment for AOD use and comorbid mental health problems among adolescents identified as being at high or severe risk of AOD use disorder during adolescent Well Visits.",[365,366,367,368],"Adolescent Alcohol Use","Mental Health Issue","Alcohol Related Disorders","Adolescents",[368,64,370,371,372],"SBIRT","Screening","Drug","2024-07-04",{"date":375,"type":40},"2024-07-08",{"date":377,"type":40},"2024-02-13",{"date":379,"type":21},"2027-08-31",{"name":381,"class":157},"Kaiser Permanente",{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":15,"sex":16,"minAge":390,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":85,"phases":394,"briefSummary":395,"conditions":396,"keywords":401,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":48},"100536294","recognition-and-early-intervention-for-alcohol-and-substance-abuse-in-adolescence-in-adolescent-100536294","NCT06262958","Recognition and Early Intervention for Alcohol and Substance Abuse in Adolescence in Adolescent","REAL-SMART: Recognition and Early Intervention for Alcohol and Substance Abuse in Adolescence, REAL\u002FSystemic Metabolic Alterations Related to Different Psychiatric Disease Categories in Adolescent","REAL-SMART","Inclusion Criteria: Admitted to the Kuopio University Hospital (KUH) adolescent psychiatric outpatient clinic during the years 2016-2019\n\nExclusion Criteria: Unable to understand the questionnaires","14 Years","19 Years",{"count":393,"type":21},800,[87],"ASSIST mini-intervention is applied in an electric form in adolescent outpatients to see if it",[61,397,60,26,398,399,400],"Substance Abuse","Substance Use Disorders","Adolescent Behavior","Adolescent Problem Behavior",[144,402,403,404,405],"substance","abuse","mini-intervention","adolescent","2024-02-08",{"date":408,"type":40},"2024-02-16",{"date":410,"type":40},"2017-08-07",{"date":412,"type":21},"2030-06-01",{"name":414,"class":157},"Kuopio University Hospital",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":85,"phases":425,"briefSummary":426,"conditions":427,"keywords":431,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":444},"100504953","the-liver-care-trial-100504953","NCT05855031","The Liver Care Trial","The Liver Care Trial: Screening for Liver Disease in Individuals Attending Treatment for Alcohol Use Disorder - a Randomized Controlled Study","Inclusion Criteria:\n\n* Attending outpatient treatment for alcohol use disorder (international classification of disease version 10: F102: alcohol dependence or F101: harmful alcohol use) at Novavi Køge or Novavi Roskilde\n* Informed written consent\n\nExclusion Criteria:\n\n* Not speaking Danish or English\n* Severe liver disease (known by the participant)","110 Years",{"count":424,"type":21},408,[87],"The goal of this clinical trial is to evaluate the efficacy of screening for liver disease with liver stiffness measurement on abstinence or light consumption after 6 months in individuals who are receiving treatment for alcohol use disorder and without a history of liver disease. The investigators will conduct a randomized controlled trial with concealed allocation comparing A) an invitation to a liver stiffness measurement, blood sampling and leaflet on alcohol-related disease (intervention) with B) an invitation to blood sampling (control). The primary outcome is 'abstinence or light consumption' (≤ 10 units\u002Fweek) throughout the last months, and assessed 6 months after randomization.",[428,31,429,61,430,26],"Alcoholic Liver Disease","Alcohol Abuse","Fibrosis, Liver",[371,432,433,434],"Fibroscan","Liver stiffness measurement","abstinence","2023-05-15",{"date":437,"type":40},"2023-05-17",{"date":439,"type":40},"2023-05-08",{"date":441,"type":21},"2027-05-01",{"name":443,"class":157},"Zealand University Hospital",2,{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":228,"enrollmentInfo":452,"targetDuration":4,"studyType":85,"phases":454,"briefSummary":455,"conditions":456,"keywords":459,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100431377","neurobiological-effects-of-transcranial-direct-current-stimulation-treatment-in-alcohol-use-disorder-100431377","NCT04897295","Neurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use Disorder","Neurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use Disorder: a Sham-controlled Trial.","Inclusion Criteria:\n\n* diagnosis of Alcohol Use Disorder (at least 12 months);\n* drug free\u002Fstable psychopharmacological therapy (one month), with the exception of guidelines treatments for alcoholic abstinence (treatment-as-usual);\n* any assumption of substances for at least 48 hours.\n\nExclusion Criteria:\n\n* presence of organic pathologies (capable of interfering with the safety of the procedure) in comorbidities;\n* presence of intellectual disability;\n* history of epileptic seizures (also in first degree relatives);\n* score\\> 12 on the Young Mania Rating Scale (Y-MRS).",{"count":453,"type":21},30,[87],"Background: Alcohol Use Disorder (AUD) is a complex psychiatric disorder, involving several brain areas and neurocircuits. Transcranial Direct Current Stimulation (tDCS) allows to stimulate superficial areas of brain using a weak electrical current. Preliminary data suggest that tDCS may reduce alcohol craving and consumption.\n\nObjectives: The main outcome is to test if tDCS can reduce alcohol craving and use and to assess the changes in BDNF and pro-BDNF levels. Secondary outcomes are the assessment of other psychiatric dimensions (mood, behavioral and cognitive alterations) associated with prolonged alcohol use.\n\nEligibility: Healthy, right-handed adults ages 18-65 who do have AUD (moderate to severe).\n\nDesign: This is a randomized, double-blind, sham-controlled study with three phases: 1) a tDCS intensive treatment phase; 2) follow-up with weekly tDCS stimulation; 3) follow-up without tDCS stimulation.\n\nParticipants will be screened with:\n\n* Psychometric Scales\n* Medical history\n* Physical exam\n* Urine tests and breathalyzer\n* After being enrolled, baseline behavioral and laboratory data will be collected. In particular, participants will undergo:\n* Psychometric Scales\n* Venous blood sample (BDNF\u002FproBDNF levels)\n\nParticipants will be randomized to real or sham tDCS arm. The stimulation will be delivered daily for five days during the first week (intensive treatment phase) and then weekly for 3 months (follow-up with stimulation). During this period patient will be tested with a behavioral and psychometric evaluation.Therefore, participants will receive 3 follow-up monthly visits without tDCS stimulation, in which behavioral and psychometric data will be collected.\n\nTreatment includes:\n\n* tDCS: The tDCS will be delivered with a stimulator connected to two sponge electrodes, soaked in a saline solution. The stimulation will be administered at a current intensity of approximately 1 mA, for the duration of 20 minutes. The anode will be placed on the right DLPFC, the cathode on the contralateral cortical area.\n* BDNF\u002FproBDNF levels: A venous blood sample will be collected before the first stimulation and after the last stimulation of the intensive-stimulation period (first week). The blood sample will be centrifuged within 20 minutes of sampling at 1000 × g for 15 minutes. Then, the serum will be aliquoted and stored at -80 ° C until analysis.\n* Repeat of screening tests and questionnaires\n* Urine toxicological screen and breathalyzer",[235,429,60,26,457,398,458],"Drug Abuse","Mental Disorder",[31,460,461,319,462,463],"transcranial Direct Current Stimulation","Non-Invasive Brain Stimulation","Brain Derived Neurotrophic Factor","Pro-Brain Derived Neurotrophic Factor","2021-10-25",{"date":466,"type":40},"2021-10-26",{"date":468,"type":21},"2021-12-01",{"date":470,"type":21},"2026-11-30",{"name":472,"class":157},"ITAB - Institute for Advanced Biomedical Technologies"]